Seminars in Nuclear Medicine
Volume 36, Issue 1 , Pages 51-72 , January 2006

Nuclear Medicine Studies of the Prostate, Testes, and Bladder

  • Suman Jana, MD
    • ,
  • M. Donald Blaufox, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to M. Donald Blaufox, MD, PhD, Montefiore Medical Center, Department of Nuclear Medicine, Albert Einstein College of Medicine at Yeshiva University, 1695A Eastchester Road, Bronx, NY 10461.

References 

  1. Grant JCB . The male pelvis . In:  Grant JCB editors. A Method of Anatomy Descriptive and Deductive . (ed 6). Baltimore, MD: Williams & Wilkins Company; 1958;p. 43–45
  2. Brooks JD . Anatomy of the lower urinary tract and male genitalia . In:  Walsh PC editors. Campbell’s Urology . (ed 8). Philadelphia, PA: Saunders (Elsevier); 2002;p. 63–65
  3. Lipsky BA . Urinary tract infections in men (Epidemiology, pathophysiology, diagnosis, and treatment) . Ann Intern Med . 1989;110:138–150
  4. Hollander JB , Diokno AC . Prostate gland disease . In:  Duthie EH ,  Katz PR editor. Practice of Geriatrics . (ed 3). Philadelphia, PA: Saunders; 1998;p. 535–544
  5. Meares EM . Prostatitis and related disorder . In:  Walsh PC ,  Gittes RF ,  Perlmutter AD , et al. editor. Campbell’s Urology . (ed 6). Philadelphia, PA: Saunders; 1992;p. 807–822
  6. Nickel JC . Prostatitis (Myths and realities) . Urology . 1998;51:362–366
  7. Krieger JN , Nyberg L , Nickel JC . NIH consensus definition and classification of prostatitis . JAMA . 1999;282:236–237
  8. Berger RE , Krieger JN , Kessler D , et al.   Case-control study of men with suspected chronic idiopathic prostatitis . J Urol . 1989;141:328–331
  9. Pavone-Macaluso M , Di Trapani D , Pavone C . Prostatitis, prostatosis and prostalgia (Psychogenic or organic disease?) . Scand J Urol Nephrol . 1991;138(suppl):77–82
  10. Meares EM . Acute and chronic prostatitis (Diagnosis and treatment) . Infect Dis Clin North Am . 1987;1:855–873
  11. Mateos JJ , Lomena F , Velasco M , et al.   Diagnosis and follow-up of acute bacterial prostatitis and orchiepididymitis detected by In-111-labeled leukocyte imaging . Clin Nucl Med . 2003;28:403–404
  12. Hall AV , Solanki KK , Vinjamuri S , et al.   Evaluation of the efficacy of 99mTc-infecton, a novel agent for detecting sites of infection . J Clin Pathol . 1998;51:215–219
  13. Vinjamuri S , Hall AV , Solanki KK , et al.   Comparison of 99mTc infecton imaging with radiolabelled white-cell imaging in the evaluation of bacterial infection . Lancet . 1996;347:233–235
  14. Choe W , Im MH , Chung JK , et al.   Imaging pelvic inflammatory disease with Tc-99m ciprofloxacin . Clin Nucl Med . 2000;25:842–844
  15. Dumarey N , Schoutens A . Renal abscess (Filling in with Tc-99m ciprofloxacin of defects seen on Tc-99m DMSA SPECT) . Clin Nucl Med . 2003;28:68–69
  16. Ryu JK , Lee SM , Seong DW , et al.   Tc-99m ciprofloxacin imaging in diagnosis of chronic bacterial prostatitis . Asian J Androl . 2003;5:179–183
  17. Carroll PR , Lee KL , Fuks ZY , et al.   Prostate cancer . In:  Devita VT ,  Hellman S ,  Rosenberg SA editor. Cancer (Principles and Practice of Oncology) . (ed 6). Philadelphia, PA: Lippincott Williams & Wilkins; 2001;p. 1418–1467
  18. Landis SH , Murray T , Bolden S , et al.   Cancer Statistics, 1998 . CA Cancer J Clin . 1998;48:6
  19. Smith RA , Cokkinides V , Eyre HJ . American Cancer Society guidelines for the early detection of cancer, 2003 . CA Cancer J Clin . 2003;53:27–43
  20. Yu KK , Hricak H . Imaging prostate cancer . Radiol Clin North Am . 2000;38:59–85
  21. Shinohara K , Wheeler TM , Scardino PT . The appearance of prostate cancer on transrectal ultrasonography (Correlation of imaging and pathological examinations) . J Urol . 1989;142:76–82
  22. Purohit RS , Shinohara K , Meng MV , et al.   Imaging clinically localized prostate cancer . Urol Clin North Am . 2003;30:279–293
  23. Hricak H , Schöder H , Pucar D , et al.   Advances in imaging in the postoperative patient with a rising prostate-specific antigen level . Semin Oncol . 2003;30:616–634
  24. Kurhanewicz J , Vigneron DB , Males RG , et al.   The prostate (MR imaging and spectroscopy. Present and future) . Radiol Clin North Am . 2000;38:115–138
  25. Costello LC , Franklin RB . Citrate metabolism of normal and malignant prostate epithelial cells . Urology . 1997;50:3–12
  26. Podo F . Tumour phospholipid metabolism . NMR Biomed . 1999;12:413–439
  27. Ak I , Stokkel MP , Pauwels EK . Positron emission tomography with 2-[18F]fluoro-2-deoxy-d-glucose in oncology: Part II. The clinical value in detecting and staging primary tumours . J Cancer Res Clin Oncol . 2000;126:560–574
  28. Delbeke D . Oncological applications of FDG PET imaging (Brain tumors, colorectal cancer, lymphoma and melanoma) . J Nucl Med . 1999;40:591–603
  29. Avril N , Menzel M , Dose J , et al.   Glucose metabolism of breast cancer assessed by 18F-FDG PET (Histologic and immunohistochemical tissue analysis) . J Nucl Med . 2001;42:9–16
  30. Bos R , van Der Hoeven JJ , van Der Wall E , et al.   Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography . J Clin Oncol . 2002;20:379–387
  31. Jerusalem BG , Beguin Y , Fassotte MF , et al.   Whole-body positron emission tomography using 18-F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical conventional tomography scan imaging . Blood . 1999;94:429–433
  32. Higashi K , Ueda Y , Sakuma T , et al.   Comparison of [(18)F]FDG PET and (201)Tl SPECT in evaluation of pulmonary nodules . J Nucl Med . 2001;42:1489–1496
  33. Schöder H , Larson SM . Positron emission tomography for prostate, bladder, and renal cancer . Semin Nucl Med . 2004;34:274–292
  34. Yoshimoto M , Waki A , Yonekura Y , et al.   Characterization of acetate metabolism in tumor cells in relation to cell proliferation (Acetate metabolism in tumor cells) . Nucl Med Biol . 2001;28:117–122
  35. Swinnen JV , Van Veldhoven PP , Timmermans L , et al.   Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains . Biochem Biophys Res Commun . 2003;302:898–903
  36. Ponde D , Oyama N , Dence C , et al.   18F-Fluoroacetate, an analogue on11C acetate for tumor imaging . J Nucl Med . 2003;44:296; (abstr)
  37. Pieterman RM , Que TH , Elsinga PH , et al.   Comparison of (11)C-choline and (18)F-FDG PET in primary diagnosis and staging of patients with thoracic cancer . J Nucl Med . 2002;43:167–172
  38. Hara T , Inagaki K , Kosaka N , et al.   Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET . J Nucl Med . 2000;41:1507–1513
  39. Torizuka T , Kanno T , Futatsubashi M , et al.   Imaging gynecologic tumors (Comparison of 11C-choline PET with 18F-FDG PET) . J Nucl Med . 2003;44:1051–1056
  40. Hara T , Kosaka N , Kishi H . Development of (18)F-fluoroethylcholine for cancer imaging with PET (Synthesis, biochemistry, and prostate cancer imaging) . J Nucl Med . 2002;43:187–199
  41. DeGrado TR , Coleman RE , Wang S , et al.   Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography (initial findings in prostate cancer) . Cancer Res . 2001;61:110–117
  42. Schober O , Duben C , Meyer G , et al.   Nonselective transport of [11Cmethyl]-l- and d-methionine into a malignant glioma . Eur J Nucl Med . 1987;13:103–105
  43. Hatazawa J , Ishiwata K , Itoh M , et al.   Quantitative evaluation of l-[methyl]-11C methionine uptake in tumor using positron emission tomography . J Nucl Med . 1989;30:1809–1813
  44. Kubota R , Kubota K , Yamada S , et al.   Methionine uptake by tumor tissue (A microautoradiographic comparison with FDG) . J Nucl Med . 1995;36:484–492
  45. Hoffer C , Laubenbacher C , Block T , et al.   Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy . Eur Urol . 1999;36:31–35
  46. Effert PJ , Bares R , Handt S , et al.   Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose . J Urol . 1996;155:994–998
  47. Liu IJ , Zafar MB , Lai YH , et al.   Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer . Urology . 2001;57:108–111
  48. Melchior SW , Fichtner J , Jones J , et al.   Changes in fluorodeoxyglucose (FDG) uptake measured by positron emission tomography (PET) in prostate cancer (CaP) patients following androgen withdrawal . J Urol . 1999;161:297
  49. Oyama N , Akino H , Suzuki Y , et al.   The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer . Jpn J Clin Oncol . 1999;29:623–629
  50. Shreve PD , Gross MD . Imaging of the pancreas and related diseases with PET carbon-11-acetate . J Nucl Med . 1997;38:1305–1310
  51. Shreve P , Chiao PC , Humes HD , et al.   Carbon-11-acetate PET imaging in renal disease . J Nucl Med . 1995;36:1595–1601
  52. Oyama N , Akino H , Kanamaru H , et al.   11C-Acetate PET imaging of prostate cancer . J Nucl Med . 2002;43:181–186
  53. Oyama N , Miller TR , Dehdashti F , et al.   11C-Acetate PET imaging of prostate cancer (Detection of recurrent disease at PSA relapse) . J Nucl Med . 2003;44:549–555
  54. Kotzerke J , Volkmer BG , Neumaier B , et al.   Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer . Eur J Nucl Med Mol Imaging . 2002;29:1380–1384
  55. Oyama N , Akino H , Suzuki Y , et al.   Prognostic value of 2-deoxy-2-[F-18]fluoro-d-glucose positron emission tomography imaging for patients with prostate cancer . Mol Imaging Biol . 2002;4:99–104
  56. Kato T , Tsukamoto E , Kuge Y , et al.   Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia (Comparison with prostate cancer) . Eur J Nucl Med Mol Imaging . 2002;29:1492–1495
  57. Matthies A , Ezziddin S , Ulrich EM , et al.   Imaging of prostate cancer metastases with (18)F-fluoroacetate using PET/CT . Eur J Nucl Med Mol Imaging . 2004;31:797
  58. Sutinen E , Nurmi M , Roivainen A , et al.   Kinetics of [(11)C]choline uptake in prostate cancer (A PET study [correction for stydy]) . Eur J Nucl Med Mol Imaging . 2004;31:317–324
  59. DeGrado TR , Baldwin SW , Wang S , et al.   Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers . J Nucl Med . 2001;42:1805–1814
  60. Nunez R , Macapinlac HA , Yeung HW , et al.   Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer . J Nucl Med . 2002;43:46–55
  61. Durkan GC , Greene DR . Elevated serum prostate specific antigen levels in conjunction with an initial prostatic biopsy negative for carcinoma (Who should undergo a repeat biopsy?) . Br J Urol Int . 1999;83:34–38
  62. Franks LM . Latent carcinoma of prostate . J Pathol Bacteriol . 1954;68:603
  63. Epstein JI . Pathology of prostatic neoplasia . In:  Walsh PC editors. Campbell’s Urology . (ed 8). Philadelphia, PA: Saunders (Elsevier); 2002;p. 3025–3033
  64. Scher HI , Isaacs JT , Zelefsky MJ , et al.   Prostate cancer . In:  Abeloff MD ,  Armitage JO ,  Niederhuber JE , et al. editor. Clinical Oncology . (ed 3). Philadelphia, PA: Churchill Livingstone; 2000;p. 1823
  65. Zhou M , Shah R , Shen R , et al.   Basal cell cocktail (34βE12 + p63) improves the detection of prostate basal cells . Am J Surg Pathol . 2003;27:365–371
  66. Chu LW , Troncoso P , Johnston DA , et al.   Genetic markers useful for distinguishing between organ-confined and locally advanced prostate cancer . Genes Chromosomes Cancer . 2003;36:303–312
  67. Grado GL , Collins JM , Kriegshauser JS , et al.   Salvage brachytherapy for localized prostate cancer after radiotherapy failure . Urology . 1999;53:2–10
  68. Mukamel E , Hanna J , deKernion JB . Pitfalls in preoperative staging in prostate cancer . Urology . 1987;30:318–321
  69. Schroder FH , van der Maas P , Beemsterboer P , et al.   Evaluation of the digital rectal examination as a screening test for prostate cancer (Rotterdam section of the European Randomized Study of Screening for Prostate Cancer) . J Natl Cancer Inst . 1998;90:1817–1823
  70. Jewett HJ , Bridge RW , Gray GF , et al.   The palpable nodule of prostate cancer (Results 15 years after radical excision) . JAMA . 1968;203:403–406
  71. Thompson IM , Ernst JJ , Gangai MP , et al.   Adenocarcinoma of the prostate (Results of routine urological screening) . J Urol . 1984;132:690–692
  72. Rees MA , Resnick MI , Oesterling JE . Use of prostate-specific antigen, Gleason score, and digital rectal examination in staging patients with newly diagnosed prostate cancer . Urol Clin North Am . 1997;24:379–388
  73. Kattan MW , Wheeler TM , Scardino PT . Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer . J Clin Oncol . 1999;17:1499–1507
  74. Abbas F , Scardino PT . The natural history of clinical prostate carcinoma . Cancer . 1997;80:827–833
  75. Gohagan JK , Prorok PC , Hayes RB , et al.   The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute (History, organization, and status) . Control Clin Trials . 2000;21(suppl 6):251S–272S
  76. Wilt TJ , Brawer MK . The Prostate Cancer Intervention Versus Observation Trial (A randomized trial comparing radical prostatectomy versus expectant management for the treatment of clinically localized prostate cancer) . J Urol . 1994;152:1910–1914
  77. Liebross RH , Pollack A , Lankford SP , et al.   Transrectal ultrasound for staging prostate carcinoma prior to radiation therapy (An evaluation based on disease outcome) . Cancer . 1999;85:1577–1585
  78. Rifkin MD , Zerhouni EA , Gatsonis CA , et al.   Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer (Results of a multi-institutional cooperative trial) . N Engl J Med . 1990;323:621–626
  79. Bates TS , Gillatt DA , Cavanagh PM , et al.   A comparison of endorectal magnetic resonance imaging and transrectal ultrasonography in the local staging of prostate cancer with histopathological correlation . Br J Urol . 1997;79:927–932
  80. Smith JA , Scardino PT , Resnick MI , et al.   Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate (Results of a prospective, multi-institutional trial) . J Urol . 1997;157:902–906
  81. Salo JO , Kivisaari L , Rannikko S , et al.   Computerized tomography and transrectal ultrasound in the assessment of local extension of prostatic cancer before radical retropubic prostatectomy . J Urol . 1987;137:435–438
  82. Platt JF , Bree RL , Schwab RE . The accuracy of CT in the staging of carcinoma of the prostate . Am J Roentgenol . 1987;149:315–318
  83. Engeler CE , Wasserman NF , Zhang G . Preoperative assessment of prostatic carcinoma by computerized tomography (Weaknesses and new perspectives) . Urology . 1992;40:346–350
  84. Levran Z , Gonzalez JA , Diokno AC , et al.   Are pelvic computed tomography, bone scan and pelvic lymphadenectomy necessary in the staging of prostatic cancer? . Br J Urol . 1995;75:778–781
  85. Gore RM , Moss AA . Value of computed tomography in interstitial 125I brachytherapy of prostatic carcinoma . Radiology . 1983;146:453–458
  86. Bartolozzi C , Menchi I , Lencioni R , et al.   Local staging of prostate carcinoma with endorectal coil MRI (Correlation with whole-mount radical prostatectomy specimens) . Eur Radiol . 1996;6:339–345
  87. Presti JC , Hricak H , Narayan PA , et al.   Local staging of prostatic carcinoma (Comparison of transrectal sonography and endorectal MR imaging) . Am J Roentgenol . 1996;166:103–108
  88. Flanigan RC , McKay TC , Olson M , et al.   Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy . Urology . 1996;48:428–432
  89. Yu KK , Scheidler J , Hricak H , et al.   Prostate cancer (Prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging) . Radiology . 1999;213:481–488
  90. Zuckier LS , Finkelstein M , Kreutzer ER , et al.   Technetium-99m antimony sulphide colloid lymphoscintigraphy of the prostate by direct transrectal injection . Nucl Med Com . 1990;11:589–596
  91. Paul DB , Loening SA , Narayana AS , et al.   Morbidity from pelvic lymphadenectomy in staging carcinoma of prostate . J Urol . 1983;129:1141–1144
  92. Gardiner RA , Fitzpatrick JM , Constable AR , et al.   Human prostatic lymphoscintigraphy (A preliminary report) . Br J Urol . 1979;51:300–303
  93. Gardiner RA , Fitzpatrick JM , Constable AR , et al.   Improved techniques in radionuclide imaging of prostatic lymp nodes . Br J Urol . 1979;51:561–564
  94. Lange PH . PROSTASCINT scan for staging prostate cancer . Urology . 2001;57:402–406
  95. Gerber G , Chodak GW . Assessment of value of routine bone scans in patients with newly diagnosed prostate cancer . Urology . 1991;37:418–422
  96. Cooperberg MR , Lubeck DP , Grossfeld GD , et al.   Contemporary trends in imaging test utilization for prostate cancer staging (Data from the cancer of the prostate strategic urologic research endeavor) . J Urol . 2002;168:491–495
  97. Oesterling JE . Using PSA to eliminate the staging radionuclide bone scan (Significant economic implications) . Urol Clin North Am . 1993;20:705–711
  98. Lee N , Fawaaz R , Olsson CA , et al.   Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients . Int J Radiat Oncol Biol Phys . 2000;48:1443–1446
  99. Shvart O , Han K , Seltzer M , et al.   Positron emission tomography in urologic oncology . Cancer Control . 2002;9:335–342
  100. Heicappell R , Muller-Mattheis V , Reinhardt M , et al.   Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-d-glucose . Eur Urol . 1999;36:582–587
  101. Kotzerke J , Prang J , Neumaier B , et al.   Experience with carbon-11 choline positron emission tomography in prostate carcinoma . Eur J Nucl Med . 2000;27:1415–1419
  102. Sanz G , Robles JE , Gimenez M , et al.   Positron emission tomography with 18fluorine-labeled deoxyglucose (utility in localized and advanced prostate cancer) . Br J Urol . 1999;84:1028–1931
  103. Kumar R , Zhuang H , Alavi A . PET in the management of urologic malignancies . Radiol Clin North Am . 2004;42:1141–1153
  104. Yeh SD , Imbriaco M , Larson SM , et al.   Detection of bony metastases of androgen-independent prostate cancer by PET–FDG . Nucl Med Biol . 1996;23:693–697
  105. Kao CH , Hsieh JF , Tsai SC , et al.   Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases . Anticancer Res . 2000;20:2189–2192
  106. Morris MJ , Akhurst T , Osman I , et al.   Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer . Urology . 2002;59:913–918
  107. Agus DB , Golde DW , Sgouros G , et al.   Positron emission tomography of a human prostate cancer xenograft (Association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal) . Cancer Res . 1998;58:3009–3014
  108. Seltzer MA , Barbaric Z , Belldegrun A , et al.   Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer . J Urol . 1999;162:1322–1328
  109. Herrmann K , Schöder H , Eberhard S , et al.   FDG PET for the detection of recurrent/metastatic prostate carcinoma in patients with rising PSA after radical prostatectomy . J Nucl Med . 2004;45:359; (abstr)
  110. Fricke E , Machtens S , Hofmann M , et al.   Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients . Eur J Nucl Med Mol Imaging . 2003;30:607–611
  111. Kotzerke J , Volkmer BG , Glatting G , et al.   Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer . Nuklearmedizin . 2003;42:25–30
  112. Price DT , Coleman RE , Liao RP , et al.   Comparison of [18F] fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and and androgen independent prostate cancer . J Urol . 2002;168:273–280
  113. de Jong IJ , Pruim J , Elsinga PH , et al.   Visualization of prostate cancer with 11C-choline positron emission tomography . Eur Urol . 2002;42:18–23
  114. de Jong IJ , Pruim J , Elsinga PH , et al.   Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET . J Nucl Med . 2003;44:331–335
  115. Macapinlac HA , Humm JL , Akhurst T , et al.   Differential metabolism and pharmacokinetics of l-[1-(11)C]-methionine and 2-[(18)F] fluoro-2-deoxy-d-glucose (FDG) in androgen independent prostate cancer . Clin Positron Imaging . 1999;2:173–181
  116. Larson SM , Morris M , Gunther I , et al.   Tumor localization of 16beta-(18)F-fluoro-5alpha-dihydrotestosterone versus (18)F-FDG in patients with progressive, metastatic prostate cancer . J Nucl Med . 2004;45:366–373
  117. Even-Sapir E , Metser U , Flusser G , et al.   Assessment of malignant skeletal disease (Initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT) . J Nucl Med . 2004;45:272–278
  118. Hetzel M , Arslandemir C , König HH , et al.   F-18 NaF PET for detection of bone metastases in lung cancer (Accuracy, cost-effectiveness, and impact on patient management) . J Bone Miner Res . 2003;18:2206–2214
  119. Schmid DT , John H , Zweifel R , et al.   Fluorocholine PET/CT in patients with prostate cancer (Initial experience) . Radiology . 2005;235:623–628
  120. D’Amico AV , Whittington R , Malkowicz SB , et al.   The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer . J Urol . 1998;160:2096–2101
  121. Partin AW , Pearson JD , Landis PK , et al.   Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases . Urology . 1994;43:649–659
  122. Pound CR , Partin AW , Eisenberger MA , et al.   Natural history of progression after PSA elevation following radical prostatectomy . JAMA . 1999;281:1591–1597
  123. Laufer M , Pound CR , Carducci MA , et al.   Management of patients with rising prostate-specific antigen after radical prostatectomy . Urology . 2000;55:309–315
  124. Parra RO , Wolf RM , Huben RP . The use of transrectal ultrasound in the detection and evaluation of local pelvic recurrences after a radical urological pelvic operation . J Urol . 1990;144:707–709
  125. Partin AW , Oesterling JE . The clinical usefulness of prostate specific antigen (Update 1994) . J Urol . 1994;152:1358–1368
  126. Kramer S , Gorich J , Gottfried HW , et al.   Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy . Br J Radiol . 1997;70:995–999
  127. Van der Wall H . The evaluation of malignancy (Metastatic bone disease) . In:  Murray IPC ,  Ell PJ editor. Nuclear Medicine in Clinical Diagnosis and Treatment . (ed 2). Edinburgh, Scotland: Churchill Livingstone; 1998;p. 1169–1184
  128. Silverman JM , Krebs TL . MR imaging evaluation with transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy . Am J Roentgenol . 1997;168:379–385
  129. Sella T , Schwartz LH , Swindle P , et al.   Endorectal coil MR in patients with PSA failure following radical prostatectomy . Radiology . 2002;225(suppl):351E; (abstr)
  130. Elgamal AA , Troychak MJ , Murphy GP . ProstaScint scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy (Analysis of 136 scans of 100 patients) . Prostate . 1998;37:261–269
  131. Smith-Jones PM , Vallabhajosula S , Navarro V , et al.   Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen (Preclinical studies in nude mice bearing LNCaP human prostate tumor) . J Nucl Med . 2003;44:610–617
  132. Lee CT , Oesterling JE . Using prostate-specific antigen to eliminate the staging radionuclide bone scan . Urol Clin North Am . 1997;24:389–394
  133. Terris MK , Klonecke AS , McDougall IR , et al.   Utilization of bone scans in conjunction with prostate-specific antigen levels in the surveillance for recurrence of adenocarcinoma after radical prostatectomy . J Nucl Med . 1991;32:1713–1717
  134. Cher ML , Bianco FJ , Lam JS , et al.   Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy . J Urol . 1998;160:1387–1391
  135. Palmer E , Henrikson K , McKusick K , et al.   Pain as an indicator of bone metastasis . Acta Radiol . 1988;29:445–449
  136. Schirrmeister H , Glatting G , Hetzel J , et al.   Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer . J Nucl Med . 2001;42:1800–1804
  137. Savelli G , Maffioli L , Maccauro M , et al.   Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions . Q J Nucl Med . 2001;45:27–37
  138. Picchio M , Messa C , Landoni C , et al.   Value of [11C]choline-positron emission tomography for re-staging prostate cancer (A comparison with [18F]fluorodeoxyglucose-positron emission tomography) . J Urol . 2003;169:1337–1340
  139. de Jong IJ , Pruim J , Elsinga PH , et al.   11C-Choline positron emission tomography for the evaluation after treatment of localized prostate cancer . Eur Urol . 2003;44:32–38
  140. Nilsson S , Kalner K , Ginman C . C-11 methionine positron emission tomography in the management of prostatic carcinoma . Antibody Immunoconjug Radiopharm . 1995;8:23–38
  141. Jana S , Abdel-Dayem HM . Role of nuclear medicine in evaluating treatment response in oncology . Nucl Med Annu . 2004;1–59
  142. Oyama N , Akino H , Suzuki Y , et al.   FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation . Nucl Med Commun . 2001;22:963–969
  143. Kurdziel KA , Figg WD , Carrasquillo JA , et al.   Using positron emission tomography 2-deoxy-2-[18F]fluoro-d-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer . Mol Imaging Biol . 2003;5:86–93
  144. Shreve PD , Grossman HB , Gross MD , et al.   Metastatic prostate cancer (Initial findings of PET with 2-deoxy-2-[F-18]fluoro-d-glucose) . Radiology . 1996;199:751–756
  145. Shimizu N , Masuda H , Yamanaka H , et al.   Fluorodeoxyglucose positron emission tomography scan of prostate cancer bone metastases with flare reaction after endocrine therapy . J Urol . 1999;161:608–609
  146. Zuckier LS . Scintigraphic evaluation of acute scrotal pain . In:  Murray IPC ,  Ell PJ editor. Nuclear Medicine in Clinical Diagnosis and Treatment . (ed 2). Edinburgh, Scotland: Churchill Livingstone; 1998;p. 111–129
  147. Nadal NS , Gitter MH , Hahn LC , et al.   Preoperative diagnosis of testicular torsion . Urology . 1973;1:478–479
  148. Holder LE , Martire JR , Holmes SER , et al.   Testicular radionuclide angiography and static imaging (Anatomy, scintigraphic interpretation, and clinical indications) . Radiology . 1977;125:739–752
  149. Motola JA , Hoory S , Smith AD , et al.   New tracer for detection of changes in testicular blood flow in rat torsion model . Urology . 1992;39:194–198
  150. Kim CK , Zuckier LS , Alavi A . The role of nuclear medicine in the evaluation of male genital tract . Semin Roentgenol . 1993;28:31–42
  151. Lutzker LG , Zuckier LS . Testicular scanning and other applications of radionuclide imaging of the genital tract . Semin Nucl Med . 1990;20:159–188
  152. Luker GD , Siegel MJ . Scrotal ultrasound in pediatric patients (Comparison of power and standard color Doppler US) . Radiology . 1996;198:381–385
  153. Bader TR , Kammerhuber F , Herneth AM . Testicular blood flow in boys as assessed at color Doppler and power Doppler sonography . Radiology . 1997;202:559–564
  154. Middleton WD , Siegel BA , Melson GL , et al.   Acute scrotal disorders (Prospective comparison of color Doppler US and testicular scintigraphy) . Radiology . 1990;177:177–181
  155. Jequier S , Patriquin H , Filiatrault D , et al.   Duplex Doppler sonographic examinations of the testis in prepubertal boys . J Ultrasound Med . 1993;12:317–322
  156. Sant GR , Kingsly KA . Testicular disorders and disorders of the scrotal contents . In:  Noble J ,  Greene HL ,  Levinson W , et al. editor. Text Book of Primary Care Medicine . (ed 3). Philadelphia, PA: Mosby; 2001;p. 1452–1460
  157. International Germ Cell Cancer Collaborative Group . International Germ Cell Consensus Classification (A prognostic factor-based staging system for metastatic germ cell cancers) . J Clin Oncol . 1997;15:594–603
  158. Jannez NK , Laifer-Narin S , Han K , et al.   Emerging technologies in uroradiologic imaging . Urol Oncol . 2003;21:317–326
  159. Fernandez EB , Moul JW , Foley JP , et al.   Retroperitoneal imaging with third and fourth generation computed axial tomography in clinical stage 1 nonseminomatous germ cell tumors . Urology . 1994;44:548–552
  160. McLeod DG , Weiss RB , Stablein DM , et al.   Staging relationships and outcome in early stage testicular cancer (A report from the Testicular Cancer Intergroup Study) . J Urol . 1991;145:1178–1183
  161. Zuckier LS . The genital tract . In:  Murray IPC ,  Ell PJ editor. Nuclear Medicine in Clinical Diagnosis and Treatment . (ed 2). Edinburgh, Scotland: Churchill Livingstone; 1998;p. 373–395
  162. Hoffer P . Status of gallium-67 in tumor detection . J Nucl Med . 1980;21:394–398
  163. Bekerman C , Hoffer PB , Bitran JD . The role of gallium-67 in the clinical evaluation of cancer . Semin Nucl Med . 1984;14:296–323
  164. Willan BD , Penney H , Castor WR , et al.   The usefulness of gallium-67 citrate scanning in testicular seminoma . Clin Nucl Med . 1987;12:813–815
  165. Uchiyama M , Kantoff PW , Kaplan WD . Gallium-67-citrate imaging in extragonadal and gonadal seminomas (Relationship to radiologic findings) . J Nucl Med . 1994;35:1624–1630
  166. Hayes RL . The medical use of gallium radionuclides (A brief history with some comments) . Semin Nucl Med . 1978;8:183–191
  167. Warren GP . Gallium scans in the evaluation of residual masses after chemotherapy for seminoma . J Clin Oncol . 1995;13:2784–2788
  168. Albers P , Bender H , Yilmaz H , et al.   Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors . Urology . 1999;53:808–811
  169. Cremerius U , Wildberger JE , Borchers H , et al.   Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results of a study in 50 patients . Urology . 1999;54:900–904
  170. Hain SF , O’Doherty MJ , Timothy AR , et al.   Fluorodeoxyglucose PET (In the initial staging of germ cell tumours) . Eur J Nucl Med . 2000;27:590–594
  171. Spermon JR , De Geus-Oei LF , Kiemeney LA , et al.   The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours . Br J Urol Int . 2002;89:549–556
  172. Stephens AW , Gonin R , Hutchins GD , et al.   Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients . J Clin Oncol . 1996;14:1637–1641
  173. Sugawara Y , Zasadny KR , Grossman HB , et al.   Germ cell tumor (Differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling) . Radiology . 1999;211:249–256
  174. Hain SF , O’Doherty MJ , Timothy AR , et al.   Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse . Br J Cancer . 2000;83:863–869
  175. Sanchez D , Zudaire JJ , Fernandez JM , et al.   18F-Fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse . Br J Urol Int . 2002;89:912–916
  176. Cremerius U , Effert PJ , Adam G , et al.   FDG PET for detection and therapy control of metastatic germ cell tumor . J Nucl Med . 1998;39:815–822
  177. De Santis M , Bokemeyer C , Becherer A , et al.   Predictive impact of 2-18fluoro-2-deoxy-d-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma . J Clin Oncol . 2001;19:3740–3744
  178. Ganjoo KN , Chan RJ , Sharma M , et al.   Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma . J Clin Oncol . 1999;17:3457–3460
  179. Bokemeyer C , Kollmannsberger C , Oechsle K , et al.   Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET . Br J Cancer . 2002;86:506–511
  180. Jana S , Bal CS , Padhy AK , et al.   Mathematical modelling of urodynamics: I. Derivation of intravesical pressure from radionuclide uroflowmetry . Ind J of Nucl Med . 1993;8:30–33
  181. Janson KL , Robert JA . Non-invasive localization of urinary tract infection . J Urol . 1977;117:624–627
  182. Hurwitz SR , Kessler WO , Alazraki NP , et al.   Gallium-67 imaging to locaize urinary-tract infections . Br J Radol . 1976;49:156–160
  183. Traisman ES , Conway JJ , Traisman HS , et al.   The localization of urinary tract infection with 99mTc glucoheptonate scintigraphy . Pediatr Radiol . 1986;16:403–406
  184. Lin WY , Lan JL , Wang SJ . Lupus cystitis on Ga-67 scans . Clin Nucl Med . 2000;25:737
  185. Palestro CJ , Cohen IR , Goldsmith SJ . Labeled leukocyte imaging in chemical cystits . Clin Nucl Med . 1993;18:75–76
  186. Gleeson FV , Gordon I . Imaging in urinary tract infection . Arch Dis Child . 1991;66:1282–1283
  187. Rothwell DL , Constable AR , Albrecht M . Radionuclide cystography in the investigation of vesicoureteric reflux in children . Lancet . 1977;1:1072–1075
  188. Thrall JH , Koff SA , Keyes JW . Diuretic radionuclide renography and scintigraphy in the differential diagnosis of hydroureteronephrosis . Semin Nucl Med . 1981;11:89–103
  189. Blaufox MD , Gruskin A , Sandler P . Scintigraphy for detection of vesico-ureteral reflux in children . J Pediatr . 1971;79:239–246
  190. Strauss BS , Blaufox MD . Estimation of residual urine and urine flow rates without urethral catheterization . J Nucl Med . 1970;11:81–84
  191. Gordon I , Peters AM , Morony S . Indirect radionuclide cystography (A sensitive technique for the detection of vesicoureteric reflux) . Pediatr Nephrol . 1990;4:604–606
  192. Pollet JE , Sharp PF , Smith FW . Radionuclide imaging for vesioco-renal reflux using intravenous 99mTc DTPA . Pediatr Radiol . 1979;8:165–167
  193. Hedman PJK , Kempi V , Voss H . Measurement of vesicoureteric reflux with intravenous 99mTc DTPA compared to radiographic cystography . Radiology . 1978;126:205–208
  194. Godley ML , Ransley PG , Parkhouse HF , et al.   Quantitation of vesiciureteric reflux by radionuclide custography and urodynamics . Pediatr Nephrol . 1990;4:485–490
  195. Backman KA , Von Garrelts B , Sundblad R . Micturation in normal women (Studies of pressure and flow) . Acta Chir Scand . 1966;132:403–412
  196. Jana S , Bal CS , Hemal AK , et al.   Theoretical modelling of pressure and flow relation of urinary bladder and correlation with conventional pressure-flow studies . Ind J Nucl Med . 1995;10:28
  197. Jemal A , Tiwari RC , Murray T , et al.   Cancer statistics, 2004 . CA Cancer J Clin . 2004;54:8–29
  198. Dalbagni G , Genega E , Hashibe M , et al.   Cystectomy for bladder cancer (A contemporary series) . J Urol . 2001;165:1111–1116
  199. Ghoneim MA , el-Mekresh MM , el-Baz MA , et al.   Radical cystectomy for carcinoma of the bladder (Critical evaluation of the results in 1,026 cases) . J Urol . 1997;158:393–399
  200. Stein JP , Lieskovsky G , Cote R , et al.   Radical cystectomy in the treatment of invasive bladder cancer (Long-term results in 1,054 patients) . J Clin Oncol . 2001;19:666–675
  201. Frank I , Cheville JC , Blute ML , et al.   Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy (Clinicopathologic features associated with outcome) . Cancer . 2003;97:2425–2431
  202. Nurmi M , Katevuo K , Puntala P . Reliability of CT in preoperative evaluation of bladder carcinoma . Scand J Urol Nephrol . 1988;22:125–128
  203. Lantz EJ , Hattery RR . Diagnostic imaging of urothelial cancer . Urol Clin North Am . 1984;11:567–583
  204. Buy JN , Moss AA , Guinet C , et al.   MR staging of bladder carcinoma (Correlation with pathologic findings) . Radiology . 1988;169:695–700
  205. Kosuda S , Kison PV , Greenough R , et al.   Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer . Eur J Nucl Med . 1997;24:615–620
  206. Ahlstrom H , Malmstrom PU , Letocha H , et al.   Positron emission tomography in the diagnosis and staging of urinary bladder cancer . Acta Radiol . 1996;37:180–185
  207. de Jong IJ , Pruim J , Elsinga PH , et al.   Visualisation of bladder cancer using (11)C-choline PET (first clinical experience) . Eur J Nucl Med Mol Imaging . 2002;29:1283–1288

PII: S0001-2998(05)00055-3

doi: 10.1053/j.semnuclmed.2005.09.001

Seminars in Nuclear Medicine
Volume 36, Issue 1 , Pages 51-72 , January 2006

Article Tools

* Image Usage & Resolution